The efficacy of captopril and 5-fluorouracil combination in the proliferation and collagen deposition of keloid fibroblast

Jesslyn Amelia; Yohanes Widodo Wirohadidjojo; Agnes Sri Siswati

doi:10.22146/ijbiotech.69505

The efficacy of captopril and 5-fluorouracil combination in the proliferation and collagen deposition of keloid fibroblast

https://doi.org/10.22146/ijbiotech.69505

Jesslyn Amelia^(1*), Yohanes Widodo Wirohadidjojo⁽²⁾, Agnes Sri Siswati⁽³⁾

(1) Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia
(2) Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia
(3) Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta 55281, Indonesia
(*) Corresponding Author

Abstract

Keloid is a benign fibroproliferative tissue growth that exceeds the initial wound margins. Captopril has been tested in vitro to reduce fibroblast proliferation and collagen deposition; thus, it has potential for use in the treatment of keloids. Meanwhile, 5‐fluorouracil (5‐FU) has already been used in keloid management. This study aimed to determine the efficacy of the combination of captopril and 5‐FU in keloid fibroblast cultures. Keloid tissues were cultured up to passages 4–7. The study consisted of a control group, captopril in various concentrations (10^‐2, 10^‐3, 10^‐4, and 10^‐5 mol/L), 5‐FU 1 mg/mL and a combination of captopril at various concentrations with 5‐FU 1 mg/mL. After 144 hours of treatment, fibroblast proliferation and collagen deposition were measured. The study showed a significant decrease in the mean index of fibroblast proliferation and collagen deposition in the group receiving captopril in various concentrations (10^‐2, 10^‐3, 10^‐4, and 10^‐5 mol/L) and the 5‐FU group against the control group (p<0.05). In the combined‐dose group, captopril at a concentration of 10^‐2 mol/L and 5‐FU showed a significant reduction in fibroblast proliferation and collagen deposition compared to the 5‐FU group and the captopril at the same dose (p<0.05). In conclusion, the combination of captopril 10^‐2 mol/L and 5‐FU 1 mg/mL is better at reducing fibroblast proliferation and collagen deposition in keloid fibroblast cultures than captopril or 5‐FU as a single therapeutic agent.

Keywords

5‐fluorouracil; captopril; collagen deposition; fibroblast proliferation; keloid fibroblast

Full Text:

PDF

References

Akaa PD, Ahachi NC, Vhriterhire AR, Agada E, Jenrola AA. 2017. Five year retrospective study on keloid management. J. Adv. Med. Med. Res. 23(6):1–8. doi:10.9734/JAMMR/2017/34824.

Chen J, Zhao S, Liu Y, Cen Y, Nicolas C. 2016. Effect of captopril on collagen metabolisms in keloid fibroblast cells. ANZ J. Surg. 86(12):1046–1051. doi:10.1111/ans.12670.

Fang Q, Wang X, Zhao W, Chen C, Zhang M, Shi B. 2018a. The source of ACE during scar formation is from both bone marrow and skin tissue. Fed. Am. Soc. Exp. Biol. 32:1–10. doi:10.1096/fj.201701575RRR.

Fang Q, Wang X, Zhao W, Ding S, Shi B. 2018b. Angiotensinconverting enzyme inhibitor reduces scar formation by inhibiting both canonical and non canonical TGFβ1 pathways. Sci. Rep. 8:1–10. doi:10.1038/s4159801821600w.

Gauglitz G, Korting H. 2011. Hypertrophic scarring and keloids : Pathomechanism and emerging treatment strategies. Mol. Med. 17(1–2):113–125. doi:10.2119/molmed.2009.00153.

Huang L, Cai YJ, Lung I, Leung BCS, Burd A. 2013. A study of the combination of triamcinolone and 5fluorouracil in modulating keloid fibroblasts in vitro. Br. J. Plast. Surg. 66(9):251–259. doi:10.1016/j.bjps.2013.06.004.

Huang L, Wong YP, Cai YJ, Lung I, Leung CS, Burd A. 2010. Lowdose 5fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. Br. J. Dermatol. 163:1181–1185. doi:10.1111/j.13652133.2010.09939.x.

Mari W, Alsabri SG, Tabal N, Younes S, Sherif A, Simman R. 2016. Novel insights on understanding of keloid scar: Article review. J. Am. Coll. Clin. Wound Spec. 7(1–3):1–7. doi:10.1016/j.jccw.2016.10.001.

Mauviel A, Verrecchia F, Wendling J, Aim E. 2003. 5Fluorouracil blocks transforming growth factor beta– induced alpha2 type I collagen gene ( COL1A2 ) expression in human fibroblasts via cJun NH 2 terminal kinase / activator protein 1 activation. Mol. Pharmacol. 64(3):707–713. 369 doi:10.1016/j.matbio.2015.05.007.

Morihara K, Takai S, Takenaka H, Sakaguchi M, Okamoto Y, Morihara T, Miyazaki M, Kishimoto S. 2006. Cutaneous tissue angiotensin converting enzyme may participate in pathologic scar formation in human skin. J. Am. Acad. Dermatol. 54(2):251–257. doi:10.1016/j.jaad.2005.09.027.

Salati SA. 2019. Keloids – An extensive review in the light of recent. J. Pakistan Assoc. Dermatol. 29(2):225–249.

Shah VV, Aldahan AS, Mlacker S, Alsaidan M. 2016. 5fluorouracil in the treatment of keloids and hypertrophic scars : A comprehensive review of the literature. doi:10.1007/s1355501601185.

Shaheen A. 2018. Comprehensive review of keloid formation. Clin. Res. Dermatol. 4(5):1–18. doi:10.15226/23781726/4/5/00168.

Vijayakumar A, Sanghvi H, Murdeshwar P. 2015. Effect of enalapril on hypertrophic scars and keloids. J. Adv. Plast. Surg. Res. 1:10–13. doi:10.31907/24142093.2015.01.3.

DOI: https://doi.org/10.22146/ijbiotech.69505